Skip to content

Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM

Diabetic Macular Edema | Diabetic Retinopathy | Diabetic Maculopathy

This prospective study aims to validate if NeoRetina, an artificial intelligence algorithm developped by DIAGNOS Inc. and trained to automatically detect the presence of diabetic retinopathy (DR) by the analysis of macula centered eye fundus photographies, can detect this disease and grade its severity.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

1. Patients of 18 years old and older;
2. Ability to provide informed consent;
3. Diagnostic for diabetes : 3a) Type 1 diabetes of a lest 5 years of evolution; or 3b) Type 2 diabetes;
4. Diabetic patient followed and refered by a physician of the Centre hospitalier de l'Université de Montréal (CHUM) : 4a) followed by an endocrinologist of the CHUM; or 4b) hospitalized at the CHUM; or 4c) on the waiting list of the Ophthalmology Clinic of the CHUM for the evaluation of DR.

Exclusion Criteria:

1. Patients less than 18 years old;
2. Inability to provide informed consent;
3. Patient who already had a treatment (surgery, laser, injection, etc.) for any retinal condition : Age-related macular degeneration (AMD), retinal vascular occlusion (RVO); etc.

Study Location

Centre hospitalier de l'Université de Montréal
Centre hospitalier de l'Université de Montréal
Montréal, Quebec
Canada

Contact Study Team

Backup Contact

Laila Reed Dagher, B.Sc.

[email protected]
514-890-8000
Primary Contact

Marie-Catherine Tessier, M.Sc.

[email protected]
514-890-8000
Study Sponsored By
Centre hospitalier de l'Université de Montréal (CHUM)
Participants Required
More Information
Study ID: NCT04699864